Bayer Aktiengesellschaft (OTCMKTS:BAYRY) is seeing a large increase in short interest

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) was the target of a significant increase in short interest during the month of September. As of September 15th, there was short interest totaling 215,900 shares, an increase of 48.1% from the August 31st total of 145,800 shares. Based on an average daily trading volume of 872,200 shares, the short interest rate is currently 0.2 days.

The Wall Street analyst weighs in

A number of brokerages recently issued reports on BAYRY. Bank of America raised Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research note on Friday, September 6th. Goldman Sachs Group started coverage on shares of Bayer Aktiengesellschaft in a research note on Thursday, May 30th. They set a “neutral” rating on the company. One equities research analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company’s stock. According to data from MarketBeat.com, Bayer Aktiengesellschaft currently has a consensus rating of “Hold”.

Get the latest stock report on Bayer Aktiengesellschaft

Bayer Aktiengesellschaft stocks rose 4.2%

OTCMKTS BAYRY traded up $0.34 during trading on Friday, reaching $8.48. 505,786 shares of the company traded hands, compared to its average volume of 1,409,716. Bayer Aktiengesellschaft has a 12-month low of $6.82 and a 12-month high of $12.08. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.27, and a quick ratio of 0.86. The firm has a market cap of $33.32 billion, a price-to-earnings ratio of -9.36 and a beta of 1.08. The company’s 50-day simple moving average is $7.60, and its two-hundred-day simple moving average is $7.45.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Your Free Report ) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.25 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.25. The company had revenue of $12 billion for the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.74% and a positive return on equity of 16.96%. As a group, sell-side analysts forecast that Bayer Aktiengesellschaft will post 1.38 EPS for the current fiscal year.

Bayer Aktiengesellschaft company profile

(Get a free report)

Bayer Aktiengesellschaft, together with its subsidiaries, operates worldwide as a life sciences company. It operates through Pharmaceuticals, Consumer Health and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialized therapy in the fields of oncology, hematology and ophthalmology; and diagnostic imaging equipment and digital solutions and contrast agents, as well as cell and gene therapy.

Read more

Get news and ratings for Bayer Aktiengesellschaft Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com’s FREE daily email newsletter.